31 Mar 2024
Assets1,294.79
Total Income723.33
EBITDA177.04
Profit After Tax100.06
NET Worth720.68
Reserves and Surplus709.54
Total Borrowing247.21
At a glance
Updated 2026-08-24Symbiotec Pharmalab is a Mainboard IPO with an issue size of ₹1,757.00 crore, proposed for listing on BSE, NSE. The issue structure includes a fresh issue of ₹150.00 crore and an offer-for-sale component of ₹1,607.00 crore.
Issue details
Listing atBSE, NSE
Issue typeBook Build Issue
Issue size₹1,757.00 Cr
Fresh issue₹150.00 Cr
Offer for sale₹1,607.00 Cr
Face value₹2
Price band₹938.00–₹988.00
Allotment27 Aug 2026
Listing31 Aug 2026
Grey market
GMP page ↗Latest GMP₹388.00
GMP / upper price39.27%
Est. listing₹1,376.00
GMP is unofficial sentiment data, not an exchange price.
Timeline
Opens24 Aug 2026
Closes26 Aug 2026
Allotment27 Aug 2026
Listing31 Aug 2026
Subscription demand
Full bidding ↗NO DATAWaiting for a verified live exchange update.
Reservation
Issue mix
QIB49.91%88,76,517 shares
− Anchor Investor29.94%53,25,909 shares
− QIB (Ex. Anchor)19.96%35,50,608 shares
NII (HNI)14.97%26,62,955 shares
− bNII > ₹10L9.98%17,75,303 shares
− sNII < ₹10L4.99%8,87,652 shares
Retail34.93%62,13,562 shares
Preferential Reservations
Employee0.19%33,408 shares
Total100.00%1,77,86,442 shares
Company
Incorporated2002
Use of proceeds
| Object | Amount |
|---|---|
| Prepayment and/or repayment, in full or in part, of all or a portion of certain outstanding borrowings availed by the Company | ₹112.50 Cr |
| General corporate purposes | — |
Financials
Full financials ↗31 Mar 2025
Assets1,579.65
Total Income755.98
EBITDA206.11
Profit After Tax96.79
NET Worth821.15
Reserves and Surplus810.03
Total Borrowing540.92
31 Mar 2026
Assets1,780.79
Total Income872.26
EBITDA231.97
Profit After Tax109.90
NET Worth1,158.64
Reserves and Surplus1,145.95
Total Borrowing387.91
Trend chart₹ crore
KPIs
| KPI | Mar 31, 2025 | Mar 31, 2026 |
|---|---|---|
| ROE | 12.66% | 11.19% |
| ROCE | 11.80% | 11.56% |
| RoNW | 11.79% | 9.48% |
| PAT Margin | 12.80% | 12.60% |
| EBITDA Margin | 27.26% | 26.59% |
| Price to Book Value | 6.58 | 5.35 |
Valuation & shareholding
Pre-IPO EPS17.82
Post-IPO EPS17.39
Pre-IPO P/E55.44
Post-IPO P/E56.81
Promoter holding pre34.47%
Promoter holding post0.00%
Market cap₹6244.43 Cr.
Peer comparison
| Company | EPS | P/E | RoNW | NAV |
|---|---|---|---|---|
| Symbiotec PharmalabSubject IPO | 19.1 | 9.48% | 184.69 |
Registrar & lead managers
Registrar
MUFG Intime India Pvt.Ltd.Lead managers
- JM Financial Ltd.
Offer documents
Data is reconciled from multiple public IPO sources. Official exchange filings and offer documents remain the source of truth. Last verified 2026-08-24.